Línea Directa Aseguradora, S.A (LNDAF) Fair Value & Analysis
Financial Services · US · Market cap $1.5B
Analysis
Línea Directa Aseguradora, S.A (LNDAF) currently trades at $1.40, while our model-based Fair Value estimate is $1.16 — implying the stock looks roughly 17.1% overvalued today. We read business quality at 95/100 (high quality), in the Financial Services sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Línea Directa Aseguradora, S.A., Compañía de Seguros y Reaseguros engages in insurance and reinsurance business in Spain and Portugal. The company operates through Automobiles, Home, Health, Other Insurance, and Other Activities segments. The Automobiles segment offers car, third party, motorcycle, theft, fire, and fleet insurance. The Home Insurance segment offers theft damage, civil liability, fire, aesthetic damage, and anti-squatting insurance. The Health Insurance segment provides health care products Vivaz brands. The Other Insurance segment offers travel assistance for credit card holders, wellness insurance, pet insurance, and multi-risk insurance. It also provides vehicle repair services through telephone and internet sales distribution channels. Línea Directa Aseguradora, S.A. was formerly known as Bankinter Aseguradora Directa, S.A. Compañía de Seguros y Reaseguros and changed its name to Línea Directa Aseguradora, S.A., Compañía de Seguros y Reaseguros in January 1995. L…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.